A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial.

Kazuhiro NishikawaKenta MurotaniKazumasa FujitaniHitoshi InagakiYusuke AkamaruShinya TokunagaMasakazu TakagiShigeyuki TamuraNaotoshi SugimotoTadashi ShigematsuTakaki YoshikawaTohru IshiguroMasato NakamuraHiroko HasegawaSatoshi MoritaYumi MiyashitaAkira TsuburayaJunichi SakamotoToshimasa Tsujinaka

Published in: Cancer chemotherapy and pharmacology (2019)

UMIN 000002571.

Keyphrases

phase iii
open label
phase ii
clinical trial
double blind
placebo controlled
early stage
study protocol
combination therapy
free survival
randomized controlled trial